Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
sipuleucel-t
cell-based immunotherapy · anticancer, cellular therapy
cell-based immunotherapyanticancer, cellular therapy
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
1 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- CladribineSevereDatabaseDDInter
Mechanism
Sipuleucel-T is designed to induce an immune cell response against prostate acidic phosphatase (PAP). Peripheral blood cells isolated from the patient are exposed to human recombinant protein PAP–GM-CSF. APCs among the blood cells take up and process PAP and direct the immune response toward the antigen.
Indications
minimally symptomatic, hormone-refractory, metastatic prostate cancer
Dosing
- Adult
- infusion on three occasions at 2-week intervals
Side effects
Common
acute infusion reactions
Drug interactions
11 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Ask House about sipuleucel-t
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team